Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic Stratification of High-risk Gastrointestinal Stromal Tumors in the Era of Targeted Therapy

23 May 2008

Abstract excerpt

In Brief Background: Recently, a trial of adjuvant imatinib for primary R0-resected intermediate and high-risk gastrointestinal stromal tumors (GISTs) significantly improved recurrence-free survival. But identifying patients having higher chances of recurrence will reduce economic losses and prevent adverse side effects caused by adjuvant treatment. Methods: Tissue samples from 93 patients with high-risk GISTs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gastrointestinal disorders and treatments
Share to Gastrointestinal Tumor Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18520229
DOI: 10.1097/sla.0b013e3181724f9d

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic Stratification of High-risk Gastrointestinal Stromal Tumors in the Era of Targeted TherapyPMID 18520229Read ↗

Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour.Semantic proximity Read ↗

Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era.Semantic proximity Read ↗

Benefit of imatinib adjuvant therapy for patients with intermediate risk gastrointestinal stromal tumor: a multi-center retrospective analysis in ChinaSemantic proximity Read ↗

Prognostic value of mutational characteristics in gastrointestinal stromal tumors: a single-center experience in 275 cases.Semantic proximity Read ↗

Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.Semantic proximity Read ↗

Clinical and Prognostic Significance of KIT exon 11 Mutation and Ki-67 Expression in Primary Gastrointestinal Stromal Tumor (GIST)Semantic proximity Read ↗

Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.Semantic proximity Read ↗

Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.Semantic proximity Read ↗

Gastric GISTs: Analysis of c-Kit, PDGFRA and BRAF mutations in relation to prognosis and clinical pathological characteristics of patients - A GIRCG study.Semantic proximity Read ↗

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.Semantic proximity Read ↗

Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.Semantic proximity Read ↗

Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.